A Phase 2 interventional study of SHR-A1811:Pyrotinib and SHR-A1811;Pertuzumab in Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-15.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 18 open to participants now, 27 under way, 12 of them phase 3. Breast Neoplasms · Jiangsu HengRui Medicine Co., Ltd..
Among the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 14th largest by planned enrollment, is one of 4 that started in 2022, is one of 4 in phase 2, and was the 25th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →18 of the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Atridia Pty Ltd. · Sites in Australia
Ages 18+
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 14 · Phase 3 20
First in 2011; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 402 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 150 across the 53 interventional studies. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
7 of the studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05424835Phase 3Jiangsu HengRui Medicine Co., Ltd.A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | 2026-12-31 |
| NCT03980054Phase 3Jiangsu HengRui Medicine Co., Ltd.A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | 2027-06 |
| NCT07024173Phase 3Shandong Suncadia Medicine Co., Ltd.A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | 2027-08 |
| NCT06974929Jiangsu HengRui Medicine Co., Ltd.A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | 2026-12 |
| NCT04993430Shanghai Hengrui Pharmaceutical Co., Ltd.A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-A1811:Pyrotinib
Drug: SHR-A1811;Pertuzumab
Drug: SHR-A1811;Adebrelimab
Drug: SHR-A1811;Albumin paclitaxel
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib:Tablet, 160mg / tablet, 80mg / tablet, oral
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab:Injection, 420 Mg (14 ml) / bottle, intravenous drip
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab:Injection, 12ml: 0.6g/bottle, intravenous drip
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel:Injection, 100mg / box, intravenous drip
This study also gives Pertuzumab. No intervention listed here names it: that was found by reading the record.
DLT(Phase I (dose exploration phase) )
Time frame: 21 days after the first administration of each subject
AE(Phase I (dose exploration phase) )
Time frame: from Day1 to 40 or 90 days after last dose
Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) )
Time frame: from Day1 to 40 or 90 days after last dose
Objective response rate(Phase II (efficacy expansion phase))
Time frame: Two years after the last subject was enrolled in the group
PK parameter: Cmin of SHR-A1811(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: Cmax of SHR-A1811(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: AUC0-t of SHR-A1811(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: Cmin of Pyrotinib(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: C4h of Pyrotinib(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: Cmin of Adebrelimab(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
Immunogenicity of SHR-A1811(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
Immunogenicity of Adebrelimab(Phase I secondary endpoint)
Time frame: through study completion, an average of 2 years
Objective Response Rate(Phase I secondary endpoint)
Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years
Duration of response(Phase I secondary endpoint)
Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years
Progression Free Survival(Phase I secondary endpoint)
Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years
AE(Phase II secondary study endpoint)
Time frame: from Day1 to 40 or 90 days after last dose
Incidence and severity of serious adverse events (SAE)(Phase II secondary study endpoint)
Time frame: from Day1 to 40 or 90 days after last dose
PK parameter: Cmin, Cmax, and AUC0-t of SHR-A1811(Phase II secondary study endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: Cmin, C4h of Pyrotinib:(Phase II secondary study endpoint)
Time frame: through study completion, an average of 2 years
PK parameter: Cmin of Adebrelimab(Phase II secondary study endpoint)
Time frame: through study completion, an average of 2 years
Immunogenicity of SHR-A1811(Phase II secondary study endpoint)
Time frame: through study completion, an average of 2 years
Immunogenicity of Adebrelimab(Phase II secondary study endpoint)
Time frame: through study completion, an average of 2 years
Duration of response(Phase II secondary study endpoint)
Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years
Progression Free Survival(Phase II secondary study endpoint)
Time frame: from first dose to disease progression, or death, whichever comes first, up to 3 years
Event-Free Survival Rate(Phase II secondary study endpoint)
Time frame: from first dose to disease progression, disease recurrence, or death, whichever comes first, up to 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Dec 2025, 43 months after the start.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 43 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu HengRui Medicine Co., Ltd. →